Endometrial carcinomas (EC) of no special molecular profile (NSMP) represent the largest molecular category of EC, comprising a mixture of tumors with different histology and molecular profiles. These facts likely point to different tumor biology, clinical outcomes, and targeted therapy responses within this molecular category. The PIK3CA is currently the only targetable kinase oncoprotein directly implicated in EC carcinogenesis. Investigating a unique single-institution cohort, we attempted to stratify NSMP ECs based on the presence of the PIK3CA pathogenic mutation. Those cases were further analyzed for other well-established-associated oncogenic driver gene mutations. Histological and clinical variables were also correlated in each case. Altogether, 175 ECs were prospectively tested by a limited custom NGS panel containing ARID1A, BCOR, BRCA1, BRCA2, CTNNB1, KRAS, MLH1, MSH2, MSH6, NRAS, PIK3CA, PMS2, POLD1, POLE, PTEN,and TP53 genes. We identified 24 PIK3CA mutated cases in the group of 80 NSMP ECs, with another co-occurring mutation in at least one oncogenic driver gene (CTNNB1, PTEN, ARID1A, KRAS, BCOR, PMS2) in 19 cases. In conclusion, a limited NGS panel can effectively test EC tissue for specific pathogenetically relevant oncogene mutations. The NSMP EC category contains 30% of the PIK3CA mutated cases. Of those, 21% contain the PIK3CA mutation as a sole EC-associated oncogene mutation, while 79% harbor at least one more mutated gene. These findings may inform future healthcare planning and improve the effectiveness of EC patient selection for the PIK3CA-targeted therapy.

Department of Gynecology and Obstetrics Medical Faculty in Pilsen Charles University Prague Czech Republic

Department of Pathology Medical Faculty in Pilsen Charles University Prague Czech Republic

Molecular Genetics Department Bioptická Laboratoř s r o Pilsen Czech Republic

Zobrazit více v PubMed

Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67–73. 10.1038/nature12113 PubMed PMC

Murciano-Goroff YR, Suehnholz PS, Drilon A, Chakravarty D (2023) Precision oncology: 2023 in review. Cancer Discov 13(12):2525–2531. 10.1158/2159-8290.CD-23-1194 PubMed PMC

Momeni-Boroujeni A, Nguyen B, Vanderbilt CM et al (2022) Genomic landscape of endometrial carcinomas of no specific molecular profile. Mod Pathol 35(9):1269–1278. 10.1038/s41379-022-01066-y PubMed PMC

van Dongen JJ, Langerak AW, Brüggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257–2317. 10.1038/sj.leu.2403202 PubMed

Santana T, Pavel A, Martinek P et al (2019) Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol 93:37–47. 10.1016/j.humpath.2019.08.009 PubMed

Carpenter CL, Duckworth BC, Auger KR, Cohen B, Schaffhausen LC, Cantley LC (1990) Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 265:19704–19711 PubMed

Samuels Y, Wang Z, Bardelli A et al (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:554 PubMed

Shayesteh L, Lu Y, Kuo WL et al (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99–102 PubMed

Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65(23):10669–10673. 10.1158/0008-5472.CAN-05-2620 PubMed

Velasco A, Bussaglia E, Pallares J et al (2006) PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37(11):1465–1472. 10.1016/j.humpath.2006.05.007 PubMed

Huang CH, Mandelker D, Schmidt-Kittler O et al (2007) The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science 318(5857):1744–1748. 10.1126/science.1150799 PubMed

Burke JE, Perisic O, Masson GR, Vadas O, Williams RL (2012) Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc Natl Acad Sci U S A 109(38):15259–15264. 10.1073/pnas.1205508109 PubMed PMC

National Center for Biotechnology Information. ClinVar. [VCV000156446.24]. https://www.ncbi.nlm.nih.gov/clinvar/variation/156446/. Accessed 25 May 2024

Barra F, Evangelisti G, Ferro Desideri L et al (2019) Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer. Expert Opin Investig Drugs 28(2):131–142. 10.1080/13543784.2018.1558202 PubMed

Willis O, Choucair K, Alloghbi A et al (2020) PIK3CA gene aberrancy and role in targeted therapy of solid malignancies. Cancer Gene Ther 27:634–644. 10.1038/s41417-020-0164-0 PubMed

Janku F, Wheler JJ, Westin SN et al (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 30(8):777–782. 10.1200/JCO.2011.36.1196 PubMed PMC

Passarelli A, Ventriglia J, Pisano C et al (2023) The way to precision medicine in gynecologic cancers: the first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer. Front Oncol 12:1088962. 10.3389/fonc.2022.1088962 PubMed PMC

Passarelli A, Carbone V, Pignata S et al (2024) Alpelisib for PIK3CA-mutated advanced gynecological cancers: first clues of clinical activity. Gynecol Oncol 183:61–67. 10.1016/j.ygyno.2024.02.029 (Published ahead of print.) PubMed

Subbiah V, Coleman N, Piha-Paul SA et al (2024) Phase I study of mTORC1/2 inhibitor sapanisertib (CB-228/TAK-228) in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun 4(2):378–387. 10.1158/2767-9764.CRC-22-0260 PubMed PMC

ClinicalTrials. https://classic.clinicaltrials.gov/ct2/show/NCT05759949. Accessed 25 May 2024

Keppler-Noreuil KM, Rios JJ, Parker VE et al (2015) PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 167A(2):287–295. 10.1002/ajmg.a.36836 PubMed PMC

Kuentz P, St-Onge J, Duffourd Y et al (2017) Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing. Genet Med 19(9):989–997. 10.1038/gim.2016.220 PubMed

Keppler-Noreuil KM, Lozier JN, Sapp JC, Biesecker LG (2017) Characterization of thrombosis in patients with Proteus syndrome. Am J Med Genet A 173(9):2359–2365. 10.1002/ajmg.a.38311 PubMed PMC

Keppler-Noreuil KM, Lozier J, Oden N et al (2019) Thrombosis risk factors in PIK3CA-related overgrowth spectrum and Proteus syndrome. Am J Med Genet C Semin Med Genet 181(4):571–581. 10.1002/ajmg.c.31735 PubMed PMC

Bosse T, Davidson B, Singh N et al (2020) Endometrioid carcinoma of the uterine corpus. In: WHO Classification of Tumours Editorial Board. Female genital tumours [Internet]. Lyon (France): International Agency for Research on Cancer; (WHO classification of tumours series, 5th ed.; vol 4). https://tumourclassification.iarc.who.int/chaptercontent/34/223. Accessed 25 May 2024